Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
AI Inc, 78% Decrease in Ordinary Profit for The Current Fiscal Year
4388 AI,Inc. 【J-GAAP】
Earnings ReportAI,Inc. <4388> [TSE Growth] announced its financial results after the market closed on May 14th (15:30). The consolidated ordinary profit for the fiscal year ending March 2025 expanded 60.5% from the previous period non-consolidated to 130 million yen. However, for the fiscal year ending March 2026 is also bleak, with an expected significant drop by 78.5% from the previous period to 28 million yen.
At the same time, the company has left the annual dividend for the current term undetermined.
In the most recent three-month period, from January to March (4Q), the consolidated ordinary profit surged 2.4 times that of the same period last year, reaching 73 million yen. However, the operating profit margin decreased from 14.1% in the same period last year to 12.8%.
Note: Since the fiscal year ending March 2025, the company has transitioned to consolidated financial statements.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2023 | 633 | 19 | 22 | 16 | 3.3 | 0 | May 11, 2023 | J-GAAP |
| Mar, 2024 | 734 | 81 | 81 | 109 | 22.2 | 0 | May 14, 2024 | J-GAAP |
| Mar, 2025 | 1,486 | 109 | 130 | -15 | -2.7 | 0 | May 14, 2025 | J-GAAP |
| YoY | +102.5% | +34.6% | +60.5% | - | - |
Full Year Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2025 Guidance | 1,486 | 109 | 130 | -15 | -2.7 | 0 | Apr 18, 2025 | J-GAAP |
| Mar, 2025 Results | 1,486 | 109 | 130 | -15 | -2.7 | 0 | May 14, 2025 | J-GAAP |
| Revision Rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Current Period Guidance
H1 Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Sep, 2024 | 400 | 9 | 8 | 0 | -0.1 | 0 | Nov 7, 2024 | J-GAAP |
| Apr - Sep, 2025 Guidance | 750 | -100 | -125 | -130 | -20.8 | - | May 14, 2025 | J-GAAP |
| YoY | +87.5% | - | - | - | -23,055.6% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 734 | 81 | 81 | 109 | 22.2 | 0 | May 14, 2024 | J-GAAP |
| Mar, 2025 | 1,486 | 109 | 130 | -15 | -2.7 | 0 | May 14, 2025 | J-GAAP |
| Mar, 2026 Guidance | 1,800 | 48 | 28 | 15 | 2.5 | - | May 14, 2025 | J-GAAP |
| YoY | +21.1% | -56.0% | -78.5% | - | - |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jan - Mar, 2024 | 220 | 31 | 30 | 56 | 11.4 | 14.1 | May 14, 2024 | J-GAAP |
| Apr - Jun, 2024 | 217 | 3 | 3 | 4 | 1.0 | 1.4 | Aug 6, 2024 | J-GAAP |
| Jul - Sep, 2024 | 183 | 6 | 5 | -4 | -1.1 | 3.3 | Nov 7, 2024 | J-GAAP |
| Oct - Dec, 2024 | 485 | 23 | 49 | -86 | -15.6 | 4.7 | Feb 5, 2025 | J-GAAP |
| Jan - Mar, 2025 | 601 | 77 | 73 | 71 | 12.7 | 12.8 | May 14, 2025 | J-GAAP |
| YoY | +173.2% | +148.4% | +143.3% | +26.8% | +11.3% |
Related Articles
Tokai Kisen, Jan-Mar (1Q) Ordinary Profit Loss Narrows
SYSMEX, 6% Increase in Net Income, Update Record High for Fifth Consecutive Term, Increased Previous Year's Dividend by 2 yen, This Fiscal Year to Increase Dividend by 6 yen
TAYCA, 4% Decrease in Ordinary Profit for The Current Fiscal Year, Dividend Raised by 2 yen
Kubota Pharma, Jan-Mar (1Q) Net Income Loss Narrows
Immuno-Biological Lab, 15% Increase in Ordinary Profit, Update Record High for Second Consecutive Term, Resuming Dividends at 6 yen for the First Time in Thirteen Terms
Rakuten, Jan-Mar (1Q) Net Income Loss Widens
Renascience, The Current Fiscal Year's Net Income Turns to Loss
ORO, Jan-Mar (1Q) Net Income Decreases by 21%
NHK SPRING, 9% Decrease in Ordinary Profit for The Current Fiscal Year
TOKYO AUTOMATIC MACHINERY, 67% Decrease in Ordinary Profit for The Current Fiscal Year, Dividend to Cut by 140 yen